Company intelligence / Profile preview

Kinetix Pharmaceuticals

Medford, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Kinetix Pharmaceuticals developed a proprietary platform for discovering orally active, small molecule protein kinase inhibitors. Its programs targeted immune, oncologic, and inflammatory diseases, with at least four proprietary compounds at the preclinical stage when acquired. No clinical or commercial-stage drugs were reached prior to Amgen’s acquisition. Proprietary small molecule protein kinase inhibitors identified for applications in autoimmune, cancer, asthma, arthritis, and inflammation; no late-stage or commercial drugs at the time of acquisition.

Therapeutic areas: OncologyImmunologyRheumatologyPulmonology
Modalities: Small molecule
Industry: Biotech

Partnerships

Amgen (acquirer)intended collaborations with large pharma/biotech for kinase inhibitors

Beyond the preview

Go deeper on Kinetix Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kinetix Pharmaceuticals.

Explore the full profile